KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Depreciation and Depletion: 2010-2024

Historic Depreciation and Depletion for Pacira BioSciences (PCRX) over the last 15 years, with Dec 2024 value amounting to $21.5 million.

  • Pacira BioSciences' Depreciation and Depletion rose 15.00% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.6 million, marking a year-over-year increase of 78.72%. This contributed to the annual value of $21.5 million for FY2024, which is 17.49% up from last year.
  • According to the latest figures from FY2024, Pacira BioSciences' Depreciation and Depletion is $21.5 million, which was up 17.49% from $18.3 million recorded in FY2023.
  • Pacira BioSciences' Depreciation and Depletion's 5-year high stood at $34.2 million during FY2022, with a 5-year trough of $12.0 million in FY2020.
  • In the last 3 years, Pacira BioSciences' Depreciation and Depletion had a median value of $21.5 million in 2024 and averaged $24.7 million.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first surged by 128.00% in 2022, then slumped by 46.49% in 2023.
  • Yearly analysis of 5 years shows Pacira BioSciences' Depreciation and Depletion stood at $12.0 million in 2020, then increased by 25.00% to $15.0 million in 2021, then spiked by 128.00% to $34.2 million in 2022, then plummeted by 46.49% to $18.3 million in 2023, then increased by 17.49% to $21.5 million in 2024.